Prevention of infectious disease caused by SARS-CoV-2
Conditions
Interventions
Administer 0.5 mL (3 micro g) VLPCOV-04 as a single intramuscular injection into the deltoid muscle of the upper arm
Sponsors
Masayuki Aboshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged 18 years or older at the time of informed consent (2) Signed written informed consent to participation in this study (3) Able to comply with the requirements during participation in the study, receive physical examinations and testing prespecified in the study protocol, complete the electronic diary (e-Diary) themselves, and report their symptoms and other information (4) Have received the 2-dose primary vaccination series with the SARS-CoV-2 RNA vaccines (5) 90 days or more elapsed from previous SARS-CoV-2 vaccination on the scheduled day of study drug inoculation
Exclusion criteria
Exclusion criteria: (1) Any flu-like symptom (findings suggestive of infection, such as pyrexia with an axillary body temperature of 37.5 degrees or higher, chills, cough, nasal discharge, headache, and myalgia) within 72 hours before vaccination with the study drugs (2) A positive SARS-CoV-2 antigen test result before vaccination with the study drugs at Visit 01 (Day 1) (3) A history of SARS-CoV-2 infection (including asymptomatic infection and deemed positivity) within 1 month before Visit 01 (Day 1) (4) Any concomitant unstable serious cardiovascular (including thrombosis), hematologic, respiratory, hepatic, renal, gastrointestinal, and/or psychoneurological disease "Unstable" is defined as: having undergone surgery or invasive procedures within 90 days before screening of this study, having required any measure such as change in the therapeutic agent in associated with worsening of disease status, or having any of the above planned during the study period. (5) Any concomitant active infection (6) Any concomitant or previous disease or condition deemed to affect evaluation of the drugs used in the study, such as immunodeficiency and autoimmune disease (7) Receiving an agent or therapy deemed to affect evaluation of the study drugs, or scheduled to receive such an agent or therapy during participation in the study (8) Previous anaphylaxis or known severe allergy to any food or pharmaceutical agent (including vaccines), etc. (9) A history of convulsion (excluding febrile seizure), Guillain-Barre syndrome, or acute disseminated encephalomyelitis (10) Any long-lasting (approximately 2 weeks as a guide) symptom from previous vaccination against SARS-CoV-2 or SARS-CoV-2 infection (11) Women who do not agree to use appropriate contraception methods throughout 90 days after vaccination with the study drugs (12) Pregnant or lactating women or those who intend to become pregnant during 90 days after vaccination with the study drugs (13) Have participated in any other clinical study or clinical research etc. and received any intervention such as an investigational drug within 90 days before screening of this study, or scheduled to participate in any other clinical study or clinical research etc. while in this study (14) Bleeding tendency which is a contraindication to intramuscular vaccination in the opinion of the principal investigator or sub-investigator (15) Ineligible for participating in this study in the opinion of the principal investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidences and severity of the following adverse events: - Solicited local adverse events which occurred through 6 days (until Day 7) after study drug inoculation - Solicited systemic adverse events which occurred through 6 days (until Day 7) after study drug inoculation - Adverse events which occurred through 4 weeks (until Day 29) after study drug inoculation | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidences of the following adverse events until Week 52 after vaccination with the study drugs - Serious adverse events - Adverse events leading to study discontinuation During the study period at or after 7 days (Day 8) of vaccination with the study drugs - SARS-CoV-2 infection rate - COVID-19 incidence rate | — |
Contacts
Public ContactAboshi Masayuki
VLP Therapeutics Japan, Inc.
Outcome results
None listed